Sign inJoin waitlistJoin the waitlist

Chad Tang

Assistant Professor, Radiation Oncology · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Radiation Oncology
University of Texas M D Anderson Cancer Center
2012–2013
Stanford University School of Medicine
2008–2012

Research

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Proceedings of the National Academy of Sciences of the United States of America · 2012 · 1,402 citations
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase…
Journal of Clinical Oncology · 2019 · 1,075 citations
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
Cell · 2010 · 943 citations

Steven Frank
39 papers
Daniel Gomez
31 papers
James Welsh
31 papers
Quynh-Nhu Nguyen
31 papers
Karen Hoffman
27 papers
David Hong
25 papers
Alex Sherry
24 papers · 24 as a resident
Brian Chapin
23 papers
Joe Chang
21 papers
Seungtaek Choi
21 papers
Tharakeswara Bathala
20 papers
Ethan Ludmir
19 papers · 5 as a resident

Clinical trials

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2023–2029
MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2020–2021
Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2019–2022
Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2018–2029